The first participants have been dosed in a Phase 1 clinical trial that Septerna is conducting to test SEP-479, its experimental oral treatment for hypoparathyroidism. The Phase 1 study is testing single and multiple doses of SEP-479 in up to 150 healthy volunteers, with the main goal of…